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O B J E C T I V E S The aim of this studywas to assess the long-termprognostic role ofmultidetector computed
tomography coronary angiography (CTA) in patients with suspected coronary artery disease (CAD).
B A C KG ROUND Use of CTA is increasing in patients with suspected CAD. Although there is a large
body of data supporting the prognostic role of CTA for major adverse cardiac events in the intermediate
term, its long-term prognostic role in patients with suspected CAD is not well studied.
METHOD S Between February 2005 and March 2008, 1,304 consecutive patients were prospectively
studied with CTA for detecting the presence and assessing extent of CAD (disease extension and
coronary plaque scores). Patients were classiﬁed according to the presence of normal coronaries and
nonobstructive (50%) and obstructive (50%) coronary lesions. The composite rates of hard cardiac
events (cardiac deaths and nonfatal myocardial infarctions) and all cardiac events (including late
revascularization) were the endpoints of the study.
R E S U L T S Seventy patients were excluded because their CTA data were uninterpretable. Of the
remaining 1,234 patients, clinical follow-up (mean 52 22 months) was obtained for 1,196 (97%). A total
of 475 events were recorded, with 136 hard events (18 cardiac deaths and 118 nonfatal myocardial
infarctions) and 123 late revascularizations. A total of 216 patients with early elective revascularizations
were excluded from the survival analysis. Signiﬁcant independent predictors of events in multivariate
analysis were multivessel disease and left main CAD. Cumulative event-free survival was 100% for hard
and all events in patients with normal coronary arteries, 88% for hard events and 72% for all events in
patients with nonobstructive CAD, and 54% for hard events and 31% for all events in patients with
obstructive CAD. Multivessel CAD was associated with a higher rate of hard cardiac events.
CONC L U S I O N S CTA provides prognostic information in patients with suspected CAD and
unknown cardiac disease, showing excellent long-term prognosis when there is no evidence of
atherosclerosis and allowing risk stratiﬁcation when CAD is present. (J Am Coll Cardiol Img 2012;5:
690–701) © 2012 by the American College of Cardiology Foundation
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691oronary artery disease (CAD) is the lead-
ing cause of morbidity and mortality (1).
Although there is a large body of data
supporting the prognostic role of multide-
ector computed tomography coronary angiography
CTA) for major adverse cardiac events in the
ntermediate term, its long-term prognostic role in
atients with suspected CAD is not well studied.
owever, data from electron beam computed to-
ography (CT) suggest that CT angiography pro-
ides an incremental value in long-term prediction
f all-cause mortality (2–8). More recently, evi-
ence that CAD severity at CTA evaluation is a
redictor of major adverse cardiac events was pro-
ided by a single study (9). The main limitations of
hese studies were the short follow-up (on average 1
ear for most of them and no longer than 2 years for
ll) and the inclusion of heterogeneous patients
ndergoing CTA because of known or suspected
AD (5,6) or for the workup of other cardiac
iseases (3,4,7–9). Thus, the aim of the present
tudy was the evaluation of the long-term prognos-
ic role of CTA in a large group of patients without
nown cardiac disease and in whom CAD was
uspected.
M A T E R I A L S A N D M E T H O D S
Patients and study protocol. The study population
onsisted of 3,421 consecutive patients who pre-
ented to our outpatient clinic or were admitted to
ur hospital for cardiac evaluation (exercise electro-
ardiogram [ECG], stress echocardiography, or in-
asive coronary angiography [ICA]) between Feb-
uary 2005 and March 2008 because of suspected
AD (elevated risk profile, new-onset chest pain,
bnormal stress test). In all, CTA was performed in
ddition to standard clinical workup. A total of
,777 patients were excluded because of known
AD (n  1,242 [586 with previous myocardial
nfarction and 656 with previous coronary revascu-
arization]) or other known cardiovascular diseases
n  535 [181 for heart failure, 45 for congenital
heart disease, 120 for significant valvular disease, 97
for cardiomyopathy, 21 for endocarditis, and 71 for
ascending aorta aneurysm]). Other exclusion crite-
ria were contraindications to contrast agents (n 
55), impaired renal function (creatinine clearance 60
ml/min) (n 100), inability to sustain a 15-s breath
hold (n  40), and cardiac arrhythmias (n  145).
hus, the analytical study population consisted of
,304 patients. The study was approved by our enstitution’s scientific and ethical committees, and
ll patients gave written informed consent. A struc-
ured interview was conducted and clinical history
cquired. The following cardiac risk factors were
ssessed before CTA: diabetes mellitus (glucose
evel of 7 mmol/l or the need for insulin or oral
ypoglycemic agents) (10), hypercholesterolemia
total cholesterol level5 mmol/l or treatment with
ipid-lowering drugs) (11), hypertension (blood pres-
ure 140/90 mm Hg or use of antihypertensive
edications) (12), positive family history of CAD
presence of CAD in first-degree relatives younger
han 55 years [male] or 65 years [female]) (13), and
urrent smoking. Pre-test probability of CAD was
etermined using the Diamond and Forrester
ethod (14). The Framingham risk score was
alculated as previously described (15).
Patient preparation, scan protocol, and image
reconstruction. Metoprolol was intravenously ad-
inistered before CTA with a titration
ose up to 20 mg in patients with heart
ate 65 beats/min. In all patients, CTA
as performed using a 64-slice scanner
64  0.625 mm collimation, 330 ms
gantry rotation time, VCT, GE Medical
Systems, Milwaukee, Wisconsin). Dose
modulation was attained with “electrocar-
diographic gating” for a maximum gantry
delivery between 40% and 80% during the
R-R interval. A bolus of 80 ml of high-
concentration contrast (Iomeron 400 mg/ml,
Bracco Imaging, Milan, Italy) was admin-
istered intravenously at 5 ml/s, followed by
50 ml of saline injected at the same infu-
sion rate. The scan was initiated according to the
bolus-tracking technique.
The coronary calcium score was assessed with
dedicated software (CaScore Package, GE Health-
care, Milwaukee, Wisconsin), and Agatston score
was recorded. Image datasets were analyzed using
volume rendering and multiplanar reconstruction
on post-processing workstations (CardioQ3 pack-
age, Advantage Workstation version 4.2, GE
Healthcare).
CTA data analysis. All CTA examinations were eval-
ated within 2 weeks by 2 expert readers unaware of
atient clinical status. In case of disagreement, a
oint reading was performed and a consensus deci-
ion was reached. Coronary arteries were divided
nto 16 segments according to the American Heart
ssociation classification (16). Each segment was
lassified as interpretable or not. Patients were
A B B
A N D
CAD
CTA
coron
ICA
angio
LMCA
artery
SIS
score
SSS
VDxcluded when proximal or mid segment orR E V I A T I O N S
A C R O N YM S
coronary artery disease
computed tomography
ary angiography
invasive coronary
graphy
 left main coronary
segment-involvement
segment-stenosis scoremore
ACE  angiotensin-conve
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692than 3 segments were uninterpretable (6). Then,
the interpretable segments were evaluated for the
presence of atherosclerotic plaques. Coronary
plaques were defined as structures 1 mm2 within
and/or adjacent to artery lumen, clearly distinguish-
able from vessel lumen, and surrounding pericardial
tissue (3). One coronary plaque was assigned per
coronary segment even in the presence of multiple
plaques. Plaque type was determined using the
following classification: 1) noncalcific (plaques with
lower density compared with the contrast-enhanced
vessel lumen); 2) calcific (high-density plaques);
and 3) mixed (noncalcific and calcific components
within a single plaque). If a segment contained
calcific and noncalcific plaques, we classified the
plaque as calcific. The number of segments with
noncalcific, calcific, and mixed plaques was re-
corded. Vessel segments were graded on the basis of
visually estimated obstruction of coronary lumen as
normal, mildly stenotic (50%), moderately ste-
acteristics of the Study Population and Patient Clinical Outcome
All Patients
(N  1,196)
Patients With Events
(n  412)
Patients W
(n 
62 11 65 10 61
782 (62) 318 (76) 467
27.2 5.2 28.1 5.6 26
131 (11) 67 (17) 64
ia 540 (45) 226 (55) 314
703 (59) 282 (68) 421
D 393 (33) 143 (35) 250
343 (29) 129 (32) 214
AD
646 (54) 213 (52) 433
245 (20) 49 (13) 196
305 (26) 144 (35) 161
514 (43) 171 (42) 343
339 (28) 77 (19) 262
343 (29) 158 (39) 185
210 (17) 84 (21) 126
71 (6) 32 (8) 39
282 (23) 116 (29) 166
298 (25) 150 (39) 148
211 (18) 92 (23) 119
116 (10) 47 (12) 69
ckers 198 (16) 85 (21) 113
311 (26) 162 (40) 149
n (%). *p  0.0001 versus patients with events. †p  0.05 versus patients with evrting enzyme; AT1  angiotensin 1; BMI  body mass index; CAD  coronary arterynotic (50% to 69%), or severely stenotic (70%).
Moderate and severe stenoses were considered as
obstructive lesions. The number of segments with
any obstructive plaque was also recorded. Patients
were divided into 3 groups: normal (no coronary
plaques), nonobstructive CAD (mild lesions), and
obstructive CAD (obstructive lesions). Moreover,
coronary arteries were evaluated using 2 methods:
presence of obstructive lesions in major epicardial
vessels and coronary plaque scores (3). To this end,
CTA scans were first analyzed, and then the num-
ber of major epicardial vessels exhibiting moderate
or severe plaques was recorded. Patients with ob-
structive CAD in diagonal or obtuse marginal
branches were included in the left anterior descend-
ing and left circumflex artery obstructive CAD
groups, respectively. In cases of moderate or severe
obstruction of the left main coronary artery
(LMCA), patients were assigned to the obstructive
CAD group even if they had other diseased vessels.
ut Events
4)
Patients With Hard
Events (n  125)
Patients Without Hard
Events (n  1,071)
1* 66 10 62 11‡
)* 92 (75) 690 (64)§
5 27.7 5.5 27.1 4.8
* 28 (23) 103 (9)‡
)* 70 (56) 470 (44)§
)* 91 (73) 612 (57)‡
) 42 (34) 351 (33)
) 35 (29) 308 (29)
) 59 (47) 587 (55)
)* 16 (13) 229 (21)§
)* 48 (40) 257 (24)‡
) 63 (51) 451 (42)
)* 25 (20) 314 (29)§
)* 35 (29) 308 (29)
) 20 (17) 190 (18)
† 10 (9) 61 (6)
)† 27 (22) 255 (24)
)* 34 (28) 264 (25)
)† 32 (26) 179 (17)§
13 (11) 103 (10)
)† 25 (21) 173 (16)
)* 45 (36) 266 (25)§
. ‡p  0.0001 versus patients with hard events. §p  0.05 versus patients withTable 1. Clinical Char
itho
78
Clinical characteristics
Age, yrs  1
Male (59
BMI .7
Diabetes (8)
Hypercholesterolem (40
Hypertension (54
Family history of CA (32
Smoking (27
Pre-test likelihood of C
Low (55
Moderate (25
High (20
Indications for CTA
Chest pain (44
Risk factors (33
Positive stress test (23
Medical therapy
ACE inhibitors (16
Nitrates (5)
Beta-blockers (21
Aspirin (18
Diuretics (15
AT1-blockers (8)
Calcium-channel blo (14
Statins (19
Values are mean  SD or ents
hard events.disease; CTA  computed tomography coronary angiography.
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693Second, we analyzed the extent of atherosclerotic
burden using 2 coronary artery plaque scores (3): 1)
the segment-involvement score (SIS) (i.e., the
number of segments [minimum 0; maximum 16]
with at least 1 plaque irrespective of the degree of
stenosis); and 2) the segment-stenosis score (SSS)
(i.e., the overall coronary artery plaque extent).
With the latter score, each coronary segment was
graded as having no to having severe plaque (i.e.,
score from 0 to 3) based on the extent of obstruction
of the coronary lumen diameter. The SSS of the 16
coronary segments was summed to yield a total
score ranging from 0 to 48. For both scores, a cutoff
of 5 was used to differentiate patients with low or
high probability of cardiac events (3).
Follow-up. Follow-up, either clinical visit or tele-
phone interview, was performed by trained re-
searchers blinded to the CTA data. Hospital re-
cords were screened for clinical events to confirm
the obtained information. Outcome measures were
a composite of hard cardiac events (cardiac deaths
and nonfatal myocardial infarctions) and all cardiac
events (cardiac deaths, nonfatal myocardial infarc-
tions, and revascularizations). All deaths were re-
viewed and classified as cardiac (death caused by
acute myocardial infarction, ventricular arrhythmia,
or refractory heart failure) or noncardiac. All revas-
cularizations were classified as early (patients un-
derwent an early elective revascularization within
Table 2. CTA Results and Patient Clinical Outcome
All Patients
(N  1,196)
Agatston score 151 (0–380)
No coronary disease 503 (42)
Nonobstructive CAD 241 (20)
Obstructive CAD 452 (38)
50% 1-vessel CAD 202 (17)
50% 2-vessel CAD 124 (10)
50% 3-vessel CAD 103 (9)
50% LMCA-CAD 23 (2)
70% 1-vessel CAD 153 (13)
70% 2-vessel CAD 80 (7)
70% 3-vessel CAD 58 (5)
70% LMCA-CAD 4 (0.3)
SIS 1 (0–4)
SSS 1 (0–7)
No. of segments with plaques 1 (0–4)
No. of segments with obstructive plaques 0 (0–2)
No. of segments with noncalciﬁed plaques 0 (0–1)
No. of segments with mixed plaques 0 (0–1)
No. of segments with calciﬁed plaques 0 (0–1)
Values are median (25th to 75th percentile) or n (%). *p  0.0001 versus patie
LMCA  left main coronary artery; SIS  segment-involvement score; SSS  segm6 months after CTA) or late. Only late revascular-
izations were considered cardiac events, whereas
patients with elective early revascularization were
excluded from the analysis. The diagnosis of non-
fatal myocardial infarction was based on the pres-
ence of typical chest pain, elevated cardiac enzymes,
and typical ECG changes (17). Cardiac enzymes
used for the diagnosis were troponin I and mass
creatine kinase-myocardial band. Nonfatal myocar-
dial infarction associated with revascularization
procedures was not included in the analysis.
Statistical analysis. Statistical analysis was per-
ormed using SAS (version 9.1.3, SAS Institute
nc., Cary, North Carolina) and SPSS 13.0 soft-
are (SPSS Inc., Chicago, Illinois). Statistical sig-
ificance was defined as p  0.05. Continuous
ariables are presented as mean  SD, and discrete
ariables as absolute numbers and percentages. To
ompare patient characteristics and CTA data,
hi-square or Fisher exact tests were used for
ategorical variables and Student t test for contin-
ous variables. When not normally distributed,
ontinuous variables were expressed as median
25th to 75th percentile range) and compared using
he nonparametric Mann-Whitney test. To identify
he association between CTA variables and out-
omes, Cox regression analysis was used. First,
nivariate analysis of clinical characteristics and
TA variables was performed to identify potential
atients With
nts (n  412)
Patients Without
Events (n  784)
Patients With Hard
Events (n  125)
Pa
74 (112–560) 88 (0–305)* 278 (115–595)
0 503 (64)* 0
55 (13) 186 (24)* 23 (18)
57 (87) 95 (12)* 102 (82)
36 (33) 66 (7)* 33 (27)
11 (27) 13 (2)* 30 (24)
90 (22) 13 (2)* 30 (24)
20 (5) 3 (0.4)* 9 (7)
31 (32) 22 (3)* 34 (27)
72 (17) 8 (13)* 20 (16)
51 (12) 7 (1)* 16 (13)
2 (0.5) 2 (0.2) 1 (1)
3 (2–6) 0 (0–4)* 4 (3–7)
6 (3–10) 0 (0–5)* 7 (4–13)
3 (2–6) 0 (0–4)* 4 (3–7)
2 (1–3) 0 (0–0)* 2 (1–3)
1 (0–2) 0 (0–0)* 1 (0–2)
1 (0–2) 0 (0–0)* 1 (0–2)
1 (0–3) 0 (0–0)* 1 (0–3)
ith events. †p  0.0001 versus patients with hard events. ‡p  0.05 versus patiP
Eve
tients Without Hard
Events (n  1,071)
2 115 (22–378)†
503 (47)†
218 (20)
3 350 (33)†
1 169 (16)‡
1 94 (9)†
73 (7)†
14 (1)†
1 119 (11)†
60 (6)†
42 (4)†
3 (0.2)
1 (0–5)†
1 (1–6)†
1 (0–5)†
0 (0–1)†
0 (0–1)†
0 (0–1)†
0 (0–1)†
nts w ents with hard events.
ent-stenosis score; other abbreviations as in Table 1.
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694predictors. Hazard ratios (HRs) were calculated
with 95% confidence intervals as an estimate of the
risk associated with a particular variable. To deter-
mine independent predictors of the composite end-
points, multivariate analysis of variables with p 
0.05 in univariate analysis was performed, adjusted
for variables with p  0.05 in univariate analysis,
including the Framingham risk score. To avoid
overfitting and multicollinearity issues, we devel-
oped 4 different models, for both all and hard
events. The first model was adjusted for coronary
artery classification in 1-vessel disease (VD), 2-VD,
3-VD, and LMCA-CAD 50% and for the
Framingham risk score; the second model was
adjusted for coronary artery classification in 1-VD,
2-VD, and 3-VD plus LMCA-CAD 70% and
for the Framingham risk score. The third model
was adjusted for coronary artery classification in
1-VD, 2-VD, 3-VD, and LMCA-CAD 50%
and for the clinical baseline characteristics. The
fourth model was adjusted for coronary artery clas-
Table 3. Clinical Characteristics and Univariate Predictors of Ev
HR (95% CI) for
All Cardiac Events
Clinical characteristics
Age 1.04 (1.03–1.06)
Male 1.76 (1.28–2.42)
BMI 1.03 (1.01–1.04)
Diabetes 2.77 (1.94–3.95)
Hypercholesterolemia 1.97 (1.46–2.65)
Hypertension 1.99 (1.45–2.72)
Family history of CAD 0.99 (0.73–1.35)
Smoking 1.05 (0.76–1.44)
Framingham risk score 1.04 (1.03–1.05)
Pre-test likelihood of CAD
Low 0.62 (0.40–0.95)
Moderate 1.05 (1.04–1.06)
High 1.72 (1.26–2.35)
Indications for CT
Chest pain 1.29 (1.01–1.64)
Risk factors 1.41 (1.04–1.79)
Positive stress test 1.62 (1.17–2.27)
Medical therapy
ACE inhibitors 1.32 (0.92–1.89)
Nitrates 1.90 (1.18–3.05)
Beta-blockers 1.47 (1.08–2.02)
Aspirin 1.98 (1.46–2.69)
Diuretics 1.72 (1.24–2.39)
AT1-blockers 1.20 (1.00–1.44)
Calcium-channel blockers 1.52 (1.08–2.16)
Statins 2.39 (1.78–3.22)CI  conﬁdence interval; HR  hazard ratio; other abbreviations as in Table 1.sification in 1-VD, 2-VD, and 3-VD plus LMCA-
CAD 70% and for the clinical baseline character-
istics. Cumulative event-free survival rates as a
function over time were obtained by the Kaplan-
Meier method. Hard and all cardiac event-free
survival curves were compared using the log-rank
test. Annual event rates were calculated by dividing
the Kaplan-Meier event rates by mean number of
years of follow-up.
R E S U L T S
Patient characteristics. Of the 1,304 patients pro-
spectively enrolled, 70 were excluded because the
CTA images were uninterpretable. Of the remain-
ing 1,234 patients, 38 were lost to follow-up and
1,196 (97%) had a complete follow-up (mean 52 
22 months, up to 76 months). Apart from being
older and more hypertensive, patients lost to
follow-up had no significant differences in clinical
characteristics and CTA results. A total of 475
p Value
HR (95% CI) for
Hard Cardiac Events p Value
0.0001 1.04 (1.02–1.05) 0.0001
0.0005 1.63 (1.08–2.44) 0.02
0.14 1.05 (1.03–1.07) 0.09
0.0001 2.68 (1.76–4.07) 0.0001
0.0001 1.76 (1.22–2.53) 0.002
0.0001 2.12 (1.41–3.19) 0.0003
0.96 0.99 (0.68–1.43) 0.98
0.79 1.00 (0.68–1.48) 0.98
0.0001 1.05 (1.03–1.06) 0.0001
0.38 0.79 (0.55–1.12) 0.18
0.02 1.01 (1.0–1.03) 0.05
0.0007 1.84 (1.28–2.65) 0.001
0.05 1.22 (1.01–1.42) 0.04
0.005 1.40 (1.02–1.72) 0.01
0.005 1.54 (1.11–2.13) 0.005
1.32 0.90 (0.61–1.56) 0.9
0.0086 1.52 (0.82–2.82) 0.18
0.0157 0.92 (0.6–1.40) 0.69
0.0001 1.17 (0.79–1.74) 0.44
0.0013 1.69 (1.13–2.53) 0.01
0.05 1.06 (0.75–1.49) 0.73
0.018 1.35 (0.87–2.09) 0.17
0.0001 1.73 (1.19–2.50) 0.004ents
o
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695events were recorded, including 136 hard events (18
cardiac deaths and 118 nonfatal myocardial infarc-
tions) and 123 late revascularizations. A total of 216
patients with early elective revascularizations were
excluded from the univariate, multivariate, and
survival analyses. The mean interval between CTA
and revascularizations was 7.3  13 months (range
1 to 60 months). Indications for CTA were chest
pain (43%), multiple cardiac risk factors (28%), and
equivocal or abnormal stress test (29%). Mean
pre-test probability of CAD was 42.5  9.9%. The
prevalence of male sex, diabetes, hypercholesterol-
emia, and hypertension was significantly higher in
patients with events than in those without events
(Table 1). The prevalence of high pre-test likelihood
of CAD was significantly higher in patients with
events than in patients without events (Table 1).
CTA results. Table 2 shows CTA results and patient
utcomes. Agatston score, SIS, SSS, and number of
egments with obstructive plaques were significantly
igher in patients with events than in patients
ithout events. The prevalence of obstructive
AD, 1-VD, 2-VD, and 3-VD was significantly
igher in patients with events than in patients
ithout events.
Univariate predictors of events. Univariate clinical
predictors of events were male sex, diabetes, hyper-
cholesterolemia, hypertension, and high pre-test
likelihood of CAD (Table 3). Univariate CTA predic-
tors of events are reported in Table 4. Regarding
Table 4. CTA Results and Univariate Predictors of Events
CTA Results
HR (95% CI
All Cardiac E
Agatston score 1.12 (1.00–1
Obstructive CAD 4.84 (3.45–6
50% 1-vessel CAD 3.18 (2.16–4
50% 2-vessel CAD 6.89 (4.49–1
50% 3-vessel CAD 7.10 (4.61–1
50% LMCA-CAD, 9.97 (4.84–2
70% 1-vessel CAD 3.70 (2.63–5
70% 2-vessel CAD 3.89 (2.47–6
70% 3-vessel CAD or 70% LMCA-CAD 4.90 (3.09–7
SIS 1.49 (1.43–1
SSS 1.16 (1.14–1
No. of segments with plaques 1.49 (1.43–1
No. of segments with obstructive plaques 1.50 (1.43–1
No. of segments with noncalciﬁed plaques 1.75 (1.61–1
No. of segments with mixed plaques 1.80 (1.64–1
No. of segments with calciﬁed plaques 1.49 (1.39–1Abbreviations as in Tables 1, 2, and 3.obstructive CAD, the HR was 5.49 for hard events
and 4.84 for all events. The HR was also signifi-
cantly increased in patients with multi-VD and
LMCA-CAD (Table 4).
Multivariate predictors of events. In multivariate
analysis, CTA characteristics that were significant
by univariate analysis were corrected for baseline
characteristics. Significant independent predictors
of events in multivariate analysis were multi-VD
and LMCA disease. The HRs were particularly
high for50% LMCA-CAD in both models (HR:
34.41 for hard events; HR: 34.46 for all events in
the model adjusted for Framingham risk score; HR:
39.6 for hard events; HR: 34.66 for all events in the
model adjusted for clinical baseline characteristics)
(Tables 5 and 6).
Survival analysis. Kaplan-Meier survival curves are
provided in Figures 1 to 4. No events occurred in
patients with normal coronary arteries. On the
contrary, the 52-month cumulative hard- and all-
event–free survival rates were 88% and 72% in
patients with nonobstructive CAD and 54% and
31% in those with obstructive CAD, respectively
(log-rank p  0.0001) (Fig. 1). The annual hard-
and all-event rates were 3.2% and 8% in patients
with nonobstructive CAD and 12.3% and 19.9% in
those with obstructive CAD, respectively. Figure 2
shows the relationship between CAD extent, ex-
pressed as number of major epicardial vessels exhib-
iting 50% stenosis, and event-free survival rate.
ts p Value
HR (95% CI) for
Hard Cardiac Events p Value
0.06 1.14 (1.00–1.19) 0.07
0.0001 5.49 (3.46–8.70) 0.0001
0.0001 3.46 (2.28–5.28) 0.0001
) 0.0001 3.58 (2.73–4.71) 0.0001
) 0.0001 4.33 (3.06–6.11) 0.0001
) 0.0001 6.02 (3.02–11.99) 0.0001
0.0001 3.98 (2.59–6.11) 0.0001
0.0001 3.96 (2.51–6.26) 0.0001
0.0001 5.51 (3.21–9.47) 0.0001
0.0001 1.38 (1.31–1.47) 0.0001
0.0001 1.13 (1.10–1.16) 0.0001
0.0001 1.36 (1.29–1.44) 0.0001
0.0001 1.38 (1.30–1.47) 0.0001
0.0001 1.41 (1.28–1.54) 0.0001
0.0001 1.48 (1.34–1.64) 0.0001
0.0001 1.31 (1.22–1.42) 0.0001) for
ven
.15)
.79)
.69)
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0.93
0.53
.20)
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696Regarding all events, cumulative event-free survival
was 48% with 1-VD, 14% with 2-VD, 16% with
3-VD and 25% with LMCA disease (log-rank p 
0.0001). Excluding revascularization procedures,
cumulative event-free survival was 71% with 1-VD,
33% with 2-VD, 41% with 3-VD and 19% with
LMCA disease (log-rank p  0.0001). The annual
hard- and all-event rates were 7.7% and 14.9% in
patients with 1-VD, 17.7% and 24.8% in those with
2-VD, 15.6% and 24.1% in those with 3-VD, and
21.5% and 21.5% in those with LMCA-CAD,
respectively. The relationship between atheroscle-
rotic burden, expressed as SIS and SSS, and event-
free survival rate is reported in Figures 3 and 4.
Regarding all events, cumulative event-free survival
was 77% with SIS5, 25% with SIS5, 85% with
SS 5, and 20% with SSS 5 (log-rank p 
.0001). Regarding hard events, cumulative event-
ree survival was 88% with SIS 5, 39% with SIS
5, 93% with SSS 5, and 43% with SSS 5
log-rank p  0.0001). The annual hard- and
ll-event rates were 3.2% and 6.5% in patients with
Table 5. Multivariate Signiﬁcant Predictors of Events, Corrected
CTA Results
HR (95% CI)
All Cardiac Ev
Model 1: 50%
Framingham risk score 1.01 (1.00–1.0
Nitrates 0.56 (0.32–0.9
Beta-blockers 1.05 (0.72–1.5
Aspirin 0.63 (0.42–0.9
Diuretics 1.64 (1.13–2.3
AT1-blockers 1.03 (0.83–1.2
Calcium-channel blockers 0.99 (0.68–1.4
Statins 1.41 (1.00–1.9
50% 1-vessel CAD 12.41 (7.92–19
50% 2-vessel CAD 24.00 (14.25–4
50% 3-vessel CAD 29.60 (17.74–4
50% LMCA-CAD 34.46 (15.53–7
Model 2: 70%
Framingham risk score 1.02 (1.00–1.0
Nitrates 0.70 (0.40–1.2
Beta-blockers 0.84 (0.57–1.2
Aspirin 0.83 (0.56–1.2
Diuretics 1.43 (0.49–2.0
AT1-blockers 0.98 (0.78–1.2
Calcium-channel blockers 0.97 (0.66–1.4
Statins 1.83 (1.30–2.5
70% 1-vessel CAD 6.91 (4.03–11
70% 2-vessel CAD 9.17 (6.12–13
70% 3-vessel CAD or 70% LMCA-CAD 11.92 (7.04–20
Abbreviations as in Tables 1 and 2.IS 5 and 16.4% and 20.1% in those with SIS5, respectively. The annual hard- and all-event
ates were 1.9% and 4.4% in patients with SSS 5
nd 15.3% and 23% in those with SSS 5,
espectively.
D I S C U S S I O N
On the basis of high diagnostic performance for
ruling out CAD and detecting obstructive coronary
stenosis, CTA is considered a reliable method for
evaluating patients with suspected CAD (2). How-
ever, data supporting a prognostic value of CTA in
this subset of patients are limited. Early studies
demonstrated that CTA is a predictor of all-cause
mortality (3,4) and of a combined endpoint that
includes all-cause mortality (5). Particularly, the
study of Ostrom et al. (4) demonstrated that cardiac
CTA with electron-beam tomography provides an
incremental long-term prognostic value in predict-
ing all-cause mortality in symptomatic patients (4).
Moreover, small studies have suggested a role of
independent predictor of cardiac events (7,8). Re-
Framingham Risk Score
s p Value
HR (95% CI) for
Hard Cardiac Events p Value
0.20 1.02 (1.00–10.3) 0.03
0.04 0.60 (0.29–1.23) 0.16
0.81 0.62 (0.38–1.02) 0.06
0.02 0.55 (0.34–0.89) 0.02
0.01 1.83 (1.18–2.85) 0.01
0.81 0.93 (0.63–1.37) 0.71
0.95 0.95 (0.60–1.52) 0.84
0.05 1.36 (0.90–2.05) 0.15
0.0001 8.76 (4.94–15.53) 0.0001
) 0.0001 18.95 (10.16–35.33) 0.0001
) 0.0001 23.11 (12.77–41.83) 0.0001
) 0.0001 34.41 (14.34–82.59) 0.0001
0.001 1.02 (1.01–1.04) 0.0002
0.21 0.85 (0.42–1.72) 0.65
0.38 0.55 (0.34–0.90) 0.01
0.37 0.63 (0.39–1.04) 0.07
0.05 1.51 (0.98–2.34) 0.05
0.85 0.87 (0.58–1.31) 0.52
0.89 0.88 (0.55–1.41) 0.60
0.0004 1.89 (1.26–2.80) 0.0002
0.0001 5.03 (2.64–9.61) 0.0001
0.0001 7.29 (4.54–11.70) 0.0001
0.0001 11.04 (6.21–19.62) 0.0001for
for
ent
2)
8)
3)
4)
7)
8)
4)
9)
.43)
0.41
9.40
6.43
3)
2)
3)
4)
6)
1)
2)
0)
.05)
.72)
.17)cently, Chow et al. (9) showed that CAD severity at
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697CTA evaluation is a predictor of major adverse
cardiac events at 16-month follow-up in a large patient
population. Very recently, the results of the CONFIRM
(Coronary CT Angiography Evaluation For Clini-
cal Outcomes: an International Multicenter Regis-
try) registry, a large, international multicenter
study, showed a strong role for CTA in the predic-
tion of all-cause mortality, with risk profiles differ-
ing for age and sex (18,19). As compared with
previous investigations, our study has longer
follow-up in a large group of very selected patients
who underwent CTA for suspected CAD. Indeed,
patients with any type of known cardiac disease
were excluded. To the best of our knowledge, our
study population is the most homogeneous among
Table 6. Multivariate Signiﬁcant Predictors of Events, Corrected
CTA Results
HR (95% CI)
All Cardiac Ev
Model 1: 50%
Age 1.00 (0.98–1.0
Male 1.03 (0.70–1.5
Diabetes 1.52 (1.02–2.2
Hypercholesterolemia 1.21 (0.84–1.7
Hypertension 1.15 (0.79–1.6
Nitrates 0.61 (0.34–1.0
Beta-blockers 1.01 (0.69–1.4
Aspirin 0.63 (0.41–0.9
Diuretics 1.50 (1.02–2.2
AT1-blockers 1.01 (0.81–1.2
Calcium-channel blockers 0.92 (0.62–1.3
Statins 1.29 (0.87–1.9
50% 1-vessel CAD 12.49 (7.98–19
50% 2-vessel CAD 24.04 (14.27–4
50% 3-vessel CAD 29.70 (17.80–4
50% LMCA-CAD 34.66 (15.64–7
Model 2: 70%
Age 1.01 (0.99–1.0
Male 1.44 (0.98–2.1
Diabetes 1.47 (0.99–2.1
Hypercholesterolemia 1.36 (0.96–1.9
Hypertension 1.37 (0.94–1.9
Nitrates 0.78 (0.44–1.3
Beta-blockers 0.81 (0.56–1.2
Aspirin 0.88 (0.58–1.3
Diuretics 1.32 (0.91–1.9
AT1-blockers 0.98 (0.77–1.2
Calcium-channel blockers 0.90 (0.61–1.3
Statins 1.57 (1.07–2.3
70% 1-vessel CAD 6.95 (4.05–11
70% 2-vessel CAD 9.07 (6.05–13
70% 3-vessel CAD or 70% LMCA-CAD 11.53 (6.84–19
Abbreviations as in Tables 1 and 2.the body of literature on the prognostic value ofCTA. Our main finding was that CTA was able to
provide long-term prognostic information in this
type of patient and may predict hard cardiac events.
Specifically, we found that patients without evi-
dence of CAD had excellent prognosis at 52
months, without any cardiac events recorded. On
the contrary, the cumulative event-free survival rate
was significantly lower in patients with CAD,
particularly in those with 3-VD or LMCA disease.
It is noteworthy that patients with nonobstructive
CAD showed a cumulative event-free survival sig-
nificantly lower than that of patients without CAD.
Overall, our study population had an intermediate
(42.5%) pre-test CAD probability, and accordingly,
the prevalence of obstructive lesions (38%) and
Baseline Variables
s p Value
HR (95% CI) for
Hard Cardiac Events p Value
0.86 1.01 (0.99–1.03) 0.60
0.88 1.02 (0.63–1.66) 0.92
0.04 1.46 (0.92–2.33) 0.11
0.30 1.10 (0.70–1.75) 0.68
0.46 1.50 (0.94–2.41) 0.09
0.09 0.67 (0.32–1.40) 0.28
0.95 0.59 (0.36–0.96) 0.03
0.03 0.60 (0.36–1.00) 0.05
0.04 1.63 (1.03–2.59) 0.04
0.93 0.90 (0.59–1.36) 0.61
0.69 0.82 (0.50–1.34) 0.42
0.21 1.27 (0.77–2.08) 0.35
0.0001 10.62 (5.94–18.96) 0.0001
) 0.0001 24.92 (13.12–47.33) 0.0001
) 0.0001 26.05 (14.29–47.47) 0.0001
) 0.0001 39.60 (16.27–96.38) 0.0001
0.49 1.01 (0.99–1.03) 0.20
0.06 1.46 (0.90–2.36) 0.13
0.05 1.67 (1.04–2.65) 0.03
0.08 1.19 (0.76–1.85) 0.44
0.10 1.65 (1.03–2.64) 0.03
0.37 0.98 (0.48–2.00) 0.95
0.28 0.53 (0.34–0.87) 0.01
0.55 0.72 (0.43–1.19) 0.20
0.15 1.31 (0.83–2.05) 0.25
0.85 0.85 (0.55–1.33) 0.48
0.60 0.78 (0.48–1.27) 0.32
0.02 1.73 (1.07–2.79) 0.02
0.0001 6.56 (3.36–12.80) 0.0001
0.0001 8.24 (5.08–13.36) 0.0001
0.0001 11.42 (6.37–20.44) 0.0001for
for
ent
2)
1)
7)
5)
7)
8)
9)
6)
1)
7)
7)
1)
.55)
0.50
9.57
6.81
2)
1)
6)
3)
9)
5)
0)
3)
7)
3)
3)
1)
.91)
.59)
.44)number of patients with events at follow-up (39%)
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poor prognosis. Abbreviation as in Figure 1.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 7 , 2 0 1 2
J U L Y 2 0 1 2 : 6 9 0 – 7 0 1
Andreini et al.
Prognostic Role of Cardiac-CT in Suspected CAD
698were relatively low. In this subgroup, CTA dem-
onstrated the best diagnostic accuracy in compari-
son with ICA, with a negative predictive value close
to 100% (2). In agreement with previous studies
that enrolled a smaller number of less homogeneous
patients with shorter follow-up (6,8), our study
confirmed that the absence of CAD at CTA is
associated with an event-free survival of 100% for
both hard and all cardiac events at the 52-month
follow-up. Therefore, this diagnostic modality can
be used to reassure patients with suspected CAD
who have equivocal results of exercise ECG, stress
single-photon emission computed tomography
(SPECT) imaging, and stress echocardiography
without the need of ICA about their outcome. Of
note, despite exercise ECG, stress SPECT imag-
ing, and stress echocardiography having lower di-
agnostic performance than CTA, their normality
has been associated with low event risk (20). A
ajor drawback of CTA in comparison with exer-
ise ECG and stress echocardiography is radiation
xposure. However, different strategies such as
ual-source CT (21), high-pitch scanning (21), and
rospective ECG triggering (22) have been shown
o reduce radiation dose.
Detection of obstructive CAD at CTA was a
trong predictor of cardiac events in univariate
nalysis (HR: 5.49 and 4.84 for hard and all events,
espectively). Kaplan-Meier survival curves con-
rmed this finding, showing an event-free survival
f 54% for hard events and 31% for all events in
hese patients. Moreover, CTA allowed prognostic
rading based on the classification in 1-VD, 2-VD,
-VD, and LMCA disease. In both univariate and
ultivariate analyses, HRs for hard and all events
ere significantly increased in patients with multi-
essel CAD and LMCA disease. Accordingly, sur-
ival curves free of hard events were progressively
educed, from 71% with 1-VD to 19% with
MCA-CAD. In 2007, Min et al. (3) demon-
trated that atherosclerotic burden assessed with
TA was able to stratify all-cause mortality in
atients who were followed for 15 months (3).
ur study showed that, in addition to having a
rognostic role when obstructive CAD was de-
ected, CTA was able to predict events on the
asis of atherosclerotic burden evaluated with
oronary artery plaque scores. Indeed, event-free
urvival significantly decreased at the 52-month
ollow-up from 85% for SSS 5 to 20% for SSS
5 considering revascularizations and from 93%Cu
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Figure 1. Kaplan-Meier Survival Curves in Patients With Normal and
Abnormal Coronary Arteries
Kaplan-Meier curves for (A) all events and (B) hard events in patients with normal coro-
nary arteries, nonobstructive coronary artery disease (CAD), and obstructive CAD, show-
ing that patients with normal coronary arteries had excellent prognosis. On the
contrary, the 52-month cumulative hard and all event-free survival rates were 88% and
72% in patients with nonobstructive CAD and 54% and 31% in those with obstructiveCu
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Figure 2. Kaplan-Meier Survival Curves in Patients Classiﬁed on the Basis of
Number of Major Epicardial Vessels Exhibiting >50% Stenosis
Kaplan-Meier curves for (A) all events and (B) hard events in patients with nonobstruc-
tive CAD, 50% 1-vessel, 50% 2-vessel, 50% 3-vessel CAD, and 50% left main cor-
onary artery (LMCA) CAD, showing that patients with multivessel and LMCA-CAD hador SSS 5 to 43% for SSS 5 excluding
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699revascularizations. Another remarkable finding was
that atherosclerotic burden maintained similar prog-
nostic value and event-free survival rate using SIS.
Another major result of this study with impor-
tant clinical implications was that found in patients
with nonobstructive CAD at CTA. In these pa-
tients, all stress tests are usually negative because
this type of lesion rarely triggers myocardial isch-
emia. Although traditional noninvasive testing in
this subset of patients suggests a prognosis similar
to that found in patients with normal coronary
arteries, our data indicated a worse long-term out-
come instead. Indeed, Kaplan-Meier survival curves
showed an event-free survival of 87% for hard
events and 69% for all events in patients with
nonobstructive CAD at the 52-month follow-up.
Thus, these patients had a cardiac event probability
intermediate between that found in patients with
normal coronary arteries and that in obstructive
CAD. This finding requires some comments. Pre-
vious studies indicated that plaque composition may
be a predictor of adverse events; demonstrated that
vulnerable plaques may occur across the full spec-
trum of stenosis severity, suggesting that nonob-
structive lesions may also contribute to coronary
events (23); and showed that lipid core size and
minimal cap thickness, 2 major determinants of
plaque vulnerability, are not related to absolute
plaque size or degree of stenosis (24). In our study,
the number of noncalcific and mixed plaques had
higher HRs by univariate analysis for hard and all
events than the number of calcific plaques. Because
nonobstructive plaques are more frequent than ob-
structive plaques, it is conceivable that coronary
occlusion and myocardial infarction are due more
frequently to moderate stenoses (25). Another pos-
sible explanation of the high prognostic value of
nonobstructive CAD in our study may reside in the
long-term follow-up. In fact, we cannot rule out
that some moderate stenoses at the time of CTA
examination could have become obstructive over
time. Nevertheless, the early identification of non-
obstructive CAD with CTA is clinically important
because it may lead to a more aggressive strategy of
cardiovascular risk factor control and modification
of clinical follow-up.
Study limitations. In interpreting these data, some
imitations should be considered. First, this was a
ingle-center study, and its results may not neces-
arily reflect the patient population of other centers.
econd, we recognize that incomplete follow-up
ay result in underreporting of cardiac events.owever, the percentage of patients with complete
ollow-up was remarkably high (97%). Third, CTA
llowed the identification of patients with obstruc-
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Figure 3. Kaplan-Meier Survival Curves in Patients Classiﬁed on
Segment-Involvement Score
Kaplan-Meier curves for (A) all events and (B) hard events in patien
involvement score (SIS) 5 and SIS 5, showing that patients with
niﬁcant poor prognosis in both analyses.
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Figure 4. Kaplan-Meier Survival Curves in Patients Classiﬁed on
Segment-Stenosis Score
Kaplan-Meier curves for (A) all events and (B) hard events in patien
stenosis score (SSS) 5 and SSS 5, showing that patients with SS10080
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ts with segment-
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the Basis of
ts with segment-
S 5 had a signiﬁ-cant poor prognosis in both analyses.
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700tive CAD, likely resulting in an increased revascu-
larization rate, which constituted a large proportion
of the composite all cardiac event endpoint. How-
ever, in our study, CTA was performed in addition
to the standard diagnostic workup; all decisions
regarding revascularization were based on symp-
toms, the presence of ischemia on noninvasive
testing, and ICA results; and patients with early
elective revascularizations were excluded from the
survival analysis. Finally, the presence of obstructive
CAD at CTA was strongly associated with hard
cardiac events not including revascularization pro-
cedures. We found a relatively high 52-month
cumulative event rate of 46% in obstructive CAD at
CTA in comparison with other clinical studies (26).
Indeed, although our population is the most homo-2009;30:362–71.
1
1
1
1
1
N Engl J Med 197nostic value of CTA in patients without known
CAD, differences in prognosis might be related to
clinical characteristics of our patients (symptomatic
for chest pain in 43% of cases and with positive
stress test in 29% of cases).
C O N C L U S I O N S
CTA provided prognostic information in patients
with unknown cardiac disease, showing excellent
long-term prognosis when there was no evidence of
atherosclerosis and allowing risk stratification when
CAD was present.
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